Key Drivers
- Strong Liquidity
- Negative Cash Flow
- Thin Equity Base
AIAI Summary
SNDX has moved beyond a pure pipeline bet into a real commercial story with strong revenue growth and gross margins, but the stock remains unattractive until Revuforj/Niktimvo scaling and upcoming readouts prove they can outpace persistent cash burn, debt, and dilution risk.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Negative Cash Flow
- •Thin Equity Base
SNDX has strong liquidity and gross margins, but persistent operating losses, negative cash flow, and a demanding valuation mean the stock still depends on improved cost control rather than current earnings power.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Weak rebound
- •Key resistance
Over the last month, SNDX fell about 17% in a clear lower-high/lower-low downtrend, with $21.50-$22.10 acting as resistance and $19.10-$20.00 as near-term support.
Sharp rebound from $19.11 to above $21.00, then faded back to $20.23
Sentiment & News
Key News Insights:
- •Revenue surge
- •EHA pipeline
- •Employee grants
Syndax posted strong Q1 revenue growth and a narrower loss on Revuforj/Niktimvo sales, while new EHA abstracts and employee grants signal continued clinical and commercial momentum.
The update is constructive for Syndax, as accelerating sales and ongoing clinical activity support a positive near-term outlook
Similar Companies in Healthcare
Other companies in the same sector with AI ratings